Canadian Proteomics Company Raises $4M in Financing Round | GenomeWeb

NEW YORK, Oct. 2 – Canadian proteomics company Interomex BioPharmaceuticals said Tuesday it raised $6.3 million Canadian ($4.0 million) in a second round of private financing.

Interomex BioPharmaceuticals of Vancouver said that the Business Development Bank of Canada led the round, which also included contributions from new investors, Ventures West and T2C2 of Montreal. Existing investors GeneChem Technologies Venture Fund and Western Technology Seed Investment Fund also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.